Dr. Xin Yi is a board-certified clinical chemist (DABCC) with broad expertise in clinical chemistry, endocrinology testing, therapeutic drug monitoring, toxicology, and clinical pharmacogenetics. She is a fellow of the AACC’s National Academy of Clinical Biochemistry (NACB), and the Co-director of the ComACC postdoctoral fellowship program at Houston Methodist Hospital. Her clinical services include supervising the professional activities in the sections of general and special chemistry, point of care, and diagnostic immunology. Prior to her current position, she completed her postdoctoral fellowship training in clinical chemistry at the University of Chicago after completing her PhD in clinical-bioanalytical chemistry at Cleveland State University.

Dr. Yi is interested in the application of new technologies, especially mass spectrometry and genetic analysis, in broader clinical diagnostic use. Her past research activities focused on developing novel diagnostic assays for hormone measurements using mass spectrometry, such as high-sensitive estradiol measurement to assist clinical management in pediatrics, men and postmenopausal women. Her studies in pharmacogenetics involved understanding the impact of genetic variations on therapeutic responses, such as responses to anticoagulant and antiplatelet agents, Warfarin and Clopidogrel. Her current research activities are focused on studying the expression of onco-proteins in tumor tissues using mass spectrometry, and utilizing this approach to aid cancer differential diagnoses and personalized cancer therapies.